AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
AstraZeneca PLC AZN on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with ...
Credit: Getty Images. Pedmark is the first FDA-approved therapy indicated to reduce the risk of cisplatin-induced hearing loss in children. Pedmark ® (sodium thiosulfate) is now available to reduce ...
Cisplatin-based chemotherapy regimens provide a survival benefit for patients with advanced or metastatic urothelial carcinoma of the bladder. Clinicians should follow established criteria for ...
To investigate whether event-free survival (EFS) can be maintained among children and adolescents with intermediate-risk (IR) malignant germ cell tumors (MGCT) if the administration of cisplatin, ...
Patients with cancer who received prophylactic intravenous (IV) magnesium before starting cisplatin had a lower risk for cisplatin-associated acute kidney injury (AKI) than those who did not receive ...
Please provide your email address to receive an email when new articles are posted on . Only about 7% of patients with cancer in the United States may benefit from genome-driven care. A novel model ...
Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said. FDA Commissioner Robert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results